Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
W0027 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | W0027 |
| 2 | EXPERIMENTAL | W0027 |
| 3 | EXPERIMENTAL | W0027 |
| 4 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| W0027 | DRUG | capsule |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Subjects aged 18-65 years, who have been diagnosed with moccasin type tinea pedis (by positive dermatophyte culture, positive potassium hydroxide/calcofluor white preparation, and a Total Signs and Symptoms Score of at least 4). * Females of childbearing potential must use con...
W0027 is an investigational small molecule developed by GSK plc for the treatment of tinea pedis, commonly known as athlete's foot. It has been studied specifically in the moccasin type of tinea pedis, a chronic form affecting the sole and side of the foot.
W0027 is being developed by GSK plc, which trades under the ticker GSK. GSK sponsored the clinical research evaluating the compound in patients with moccasin type tinea pedis.
W0027 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The Phase 1 trial evaluating it has been completed.
W0027 has been evaluated in one clinical trial, NCT00509275, titled a study to evaluate efficacy and safety of three W0027 regimens in the treatment of moccasin type tinea pedis. The trial was Phase 1, completed, randomized, double blind, and placebo controlled, enrolling 120 participants across the United States and Australia.
The W0027 trial NCT00509275 was a randomized, double blind, placebo controlled Phase 1 study. It enrolled 120 adults aged 18 years and older of all sexes and evaluated three W0027 regimens in patients with moccasin type tinea pedis. The study was conducted in the United States and Australia and has been completed.